GlobeNewswire: Anavex Life Sciences Corp. Contains the last 10 of 348 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T11:02:37ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/25/2851518/0/en/Anavex-Life-Sciences-to-Present-at-the-23rd-Annual-Needham-Virtual-Healthcare-Conference.html?f=22&fvtc=4&fvtv=20647Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference2024-03-25T11:30:00Z<![CDATA[NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference, April 8 – 11, 2024. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company scheduled at 8:45 AM (ET) on Monday, April 8th, 2024.]]>https://www.globenewswire.com/news-release/2024/03/18/2847701/0/en/Anavex-Life-Sciences-Initiates-Placebo-Controlled-U-S-Phase-2-Clinical-Trial-of-ANAVEX-3-71-in-Schizophrenia.html?f=22&fvtc=4&fvtv=20647Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia2024-03-18T11:30:00Z<![CDATA[First patient screened ahead of schedule]]>https://www.globenewswire.com/news-release/2024/02/26/2835035/0/en/Anavex-Life-Sciences-to-Present-at-the-44th-Annual-TD-Cowen-Health-Care-Conference.html?f=22&fvtc=4&fvtv=20647Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference2024-02-26T12:30:00Z<![CDATA[NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the 44th Annual TD Cowen Health Care Conference, March 4-6, 2024. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company in a session scheduled at 1:30 PM (ET) on Monday, March 4th, 2024, at the Boston Marriott Copley Place in Boston, MA.]]>https://www.globenewswire.com/news-release/2024/02/07/2825082/0/en/Anavex-Life-Sciences-Reports-Fiscal-2024-First-Quarter-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=20647Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update2024-02-07T12:30:00Z<![CDATA[Company to host a webcast today at 8:30 a.m. Eastern Time]]>https://www.globenewswire.com/news-release/2024/02/01/2821882/0/en/Anavex-Life-Sciences-to-Announce-Fiscal-2024-First-Quarter-Financial-Results-on-Wednesday-February-7th-2024.html?f=22&fvtc=4&fvtv=20647Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 20242024-02-01T12:30:00Z<![CDATA[Webcast and Conference Call To be Held Wednesday, February 7th, 2024, 8:30 am ET Webcast and Conference Call To be Held Wednesday, February 7th, 2024, 8:30 am ET]]>https://www.globenewswire.com/news-release/2024/01/24/2815160/0/en/Anavex-Life-Sciences-Reports-Publication-of-ANAVEX-3-71-in-Clinical-Journal-Confirming-Pharmacokinetic-Dose-Proportionality-of-ANAVEX-3-71-in-Humans.html?f=22&fvtc=4&fvtv=20647Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans2024-01-24T12:30:00Z<![CDATA[NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced a peer-reviewed publication in Clinical Pharmacology in Drug Development, findings from the ANAVEX®3-71 first-in-human study which achieved its safety objectives. The publication is entitled, ‘Population-Based Characterization of the Pharmacokinetics and Food Effect of ANAVEX3-71, a Novel Sigma-1 Receptor and Allosteric M1 Muscarinic Receptor Agonist in Development for Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer Disease’.1 The publication reports the Population-based characterization of the Pharmacokinetics (PK) and food effect of ANAVEX®3-71 as part of the single ascending dose study in healthy participants with the primary objective of assessing dose proportionality of ANAVEX®3-71, and to characterize the effect of food on the PK of ANAVEX®3-71.]]>https://www.globenewswire.com/news-release/2024/01/16/2809762/0/en/Anavex-Life-Sciences-Announces-U-S-Phase-2-Clinical-Trial-of-ANAVEX-3-71-in-Schizophrenia.html?f=22&fvtc=4&fvtv=20647Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia2024-01-16T12:30:00Z<![CDATA[Placebo-controlled Phase 2 trial cleared by the FDA – Trial to begin in Q2 2024]]>https://www.globenewswire.com/news-release/2024/01/08/2805328/0/en/Anavex-Life-Sciences-Announces-Grant-of-U-S-Patent-Covering-Blarcamesine-ANAVEX-2-73-for-Treatment-of-Neurodevelopmental-Disorders.html?f=22&fvtc=4&fvtv=20647Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders2024-01-08T12:30:00Z<![CDATA[Grant of Its Newest U.S. Patent Expands Anavex’s Intellectual Property Portfolio in Neurologic Indications Grant of Its Newest U.S. Patent Expands Anavex’s Intellectual Property Portfolio in Neurologic Indications]]>https://www.globenewswire.com/news-release/2024/01/03/2803192/0/en/Anavex-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=20647Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference2024-01-03T12:30:00Z<![CDATA[NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference. Anavex’s President and Chief Executive Officer, Christopher U Missling, PhD, is scheduled to present at the conference at the Westin St. Francis in San Francisco, CA on January 11, 2024 at 10:30am Pacific Standard Time (PST).]]>https://www.globenewswire.com/news-release/2024/01/02/2802638/0/en/Anavex-Life-Sciences-Provides-an-Update-on-Rett-Syndrome-Program.html?f=22&fvtc=4&fvtv=20647Anavex Life Sciences Provides an Update on Rett Syndrome Program2024-01-02T13:00:00Z<![CDATA[Anavex Announces Topline Results from Phase 2/3 EXCELLENCE Clinical Study in Pediatric Rett Syndrome]]>